This is a preview of subscription content, log in via an institution to check access.
Notes
Source: R&D Insight, Adis International
Intercell will be profiled in an upcoming issue of Pharmaceutical & Diagnostic Innovation.
Source: R&D Insight, Adis International.
American Association of Cancer Researchers (AACR), US National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC).
References
European Biotechnology. Intercell. Acambis JE trial start does not lead us to change numbers. New York: Lehman Brothers Global Equity Research, 2005
Acambis. Acambis achieves major milestone in JE vaccine development with start of pivotal phase lll clinical testing Media release: 15 Nov 2005
Novartis. Exjade, a breakthrough once-daily oral iron chelator, receives first approval worldwide in the US. Media release: 3 Nov 2005
European Pharmaceuticals. Novartis. Operating results. 3Q05 results & Hexal/Eon integration New York: Lehman Brothers Global Equity Research, 2005
SciWords. Phenoxodiol produces anti-cancer responses in women with cervical cancer. Media release: 17 Nov 2005
SciWords. Phenoxodiol delays tumor progression in hormone refractory prostate cancer. Media release: 17 Nov 2005-11-21
Rights and permissions
About this article
Cite this article
Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 3, 17–19 (2005). https://doi.org/10.1007/BF03257014
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03257014